Stockwinners Market Radar for May 12, 2020 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:08 EDT Harley-Davidson CEO buys 99K shares of common stock - In a regulatory filing, Harley-Davidson disclosed that its CEO Jochen Zeitz bought 98.9K shares of common stock on May 8th. The total transaction size was $2.1M.

19:51 EDT Varian Medical discloses $164M in goodwill impairment charge - As part of its 10-Q filed earlier today, Varian Medical states: "Due to certain indicators identified related to the Company's Interventional Solutions reporting unit in the second quarter of fiscal year 2020, including a significant decrease in near term revenue projections due to COVID-19, the Company identified a triggering event and performed an interim impairment test on its $164.3 million of goodwill in its Interventional Solutions reporting unit, within the Other reportable operating segment. The fair value of the Interventional Solutions' reporting unit was in excess of its carrying value by approximately $20 million, or 7%. Management believes the methodology and assumptions used to calculate the fair value to be reasonable. However, the Interventional Solutions reporting unit could be at risk for a future goodwill impairment if there are adjustments to certain assumptions used in the fair value calculation, including revenue growth rates, operating margins, and weighted-average cost of capital and/or working capital requirements. Given the uncertain impact of COVID-19 and/or other market factors on the Company's business, its cash flow projections for this business could decrease in the future, which could lead to an impairment of goodwill."

18:59 EDT Alcon cannot provide FY20 guidance due to COVID-19 - The company states: "Due to the uncertain scope and duration of the ongoing COVID-19 outbreak, the Company is unable to provide an estimate for financial results for the full year 2020. The Company is actively managing working capital, cash flow and expenses and prioritizing capital allocation needs to preserve liquidity. In addition, the Company is focused on inventory management and preparing its commercial programs to support customer and patient needs as markets reopen. While second quarter results will be negatively impacted by the health crisis, given the critical nature of eye care, customer demand is expected to resume when underlying conditions normalize and gradually lead to an improvement in the back half of the year."

18:50 EDT AT&T CFO: Moving forward with transformation plans on costs, efficiencies - John Stephens, senior executive vice president and CFO of AT&T spoke at the MoffettNathanson Media & Communications Summit, where he provided an update to shareholders. Stephens discussed AT&T's commitment to its customers and employees during the Coronavirus pandemic. He said it is difficult to predict the length or the depth of the economic impact from the pandemic or its effect on the company's overall business. However, Stephens said that with the resiliency of AT&T's wireless, broadband and enterprise businesses, he has confidence in the company's ability to continue to generate strong cash flow to invest in key capital areas including fiber, 5G and HBO Max, comfortably cover its dividend and pay down debt. Additionally, Stephens said the company is moving forward with its transformation plans on operational costs and efficiencies.

18:32 EDT Apple director sells 4.5K shares of common stock - In a regulatory filing, Apple disclosed that its Chief Accounting Officer Chris Kondo sold 4.5K shares of common stock on May 8th. The total transaction size was $1.37M.

18:02 EDT Tenneco names Dennis Letham as board chairman - Tenneco announced that its board of directors has appointed Dennis Letham, formerly Lead Independent Director, as its new Chairman. Letham succeeds Gregg M. Sherrill, who served as non-executive Chairman of the Board since 2018, and as Chairman for over 10 years after joining Tenneco in January of 2007 as the company's CEO. The appointment is effective immediately. Sherrill will remain a member of the Board and announced that he intends to retire prior to next year's annual meeting of stockholders.

17:58 EDT Etsy's Reiff sells 8,504 common shares - In a regulatory filing, Etsy director Melissa Reiff disclosed the sale of 8,504 common shares of the company on May 11 at a price of $81 per share.

17:54 EDT SPDR Gold Shares holdings rise to 1,083.66MT from 1,081.07MT - This is the highest level of holdings since April of 2013.

17:51 EDT Facebook's Instagram takes steps to make users feel safe - In a post on its blog page "Today, we're sharing the fifth edition of our Community Standards Enforcement report which tracks our progress to keep Facebook and Instagram safe. In addition to this report, we're announcing new features that mark the continuation of our effort to lead the industry in the fight against online bullying.First, we're launching a new feature to help people manage multiple unwanted interactions at once. We know it can feel overwhelming to manage a rush of negative comments, so we've been testing the ability to delete comments in bulk, as well as block or restrict multiple accounts that post negative comments. Early feedback has been encouraging, and we've found that it helps people, especially with larger followings, maintain a positive environment on their account." Reference Link

17:35 EDT Wyndham Hotels & Resorts sets quarterly dividend of 8c vs. 32c in prior quarter - The dividend is payable June 30, 2020 to shareholders of record as of June 15, 2020.

17:29 EDT Danaher General Counsel sells 2.9K shares of common stock - In a regulatory filing, Danaher disclosed that its General Counsel Brian Ellis sold 2,870 shares of common stock on May 8th. The total transaction size was $469K.

17:25 EDT Borr Drilling gets NYSE listing requirement notice - Borr Drilling announced that the company has received written notice from the NYSE that the Company is not in compliance with the NYSE continued listing standard with respect to the minimum average share price required by the NYSE because the average closing price of its common shares had fallen below $1.00 per share over a period of 30 consecutive trading days. The company has responded to the NYSE to confirm its intent to cure this non-compliance. During this period, the company's common shares will continue to be traded on the NYSE subject to the company's compliance with other applicable NYSE listing requirements.

17:23 EDT Scorpio Services Holding buys 100K shares of Scorpio Tankers in open market - Scorpio Tankers announced that Scorpio Services Holding Limited, a related party, has purchased 100,000 common shares of the company at an average price of $17.36 per share in the open market. The company currently has 58,672,080 common shares outstanding, of which the Scorpio Group of companies, including SSH, owns 2,657,839 or 4.5%.

17:11 EDT Natera, Illumina reach settlement over patent suit in California - According to a regulatory filing, on May 8, 2020, Natera (NTRA) and Illumina (ILMN) reached a settlement with respect to their patent infringement action in the United States District Court for the Northern District of California relating to Illumina's U.S. Patent No. 9,493,831 and Natera's U.S. Patent No. 8,682,592. The Settlement resolves and dismisses all of the claims in the Action which relate to NIPT and pre-implantation genetic screening and diagnosis activities occurring before the date of the Settlement. The Settlement does not impact the ongoing inter partes review proceeding in the United States Patent and Trademark Office, or the pending patent opposition proceedings against European Patent No. 3006573. Natera and Illumina also entered into a License Agreement dated May 8, 2020 pursuant to which, among others, Natera has granted Illumina a non-exclusive, perpetual worldwide license to certain of Natera's intellectual property in the '592 Patent family. The foregoing license is limited to certain uses of massively parallel sequencing in the fields of NIPT and PGS/PGD, and excludes certain approaches. In order to maintain their respective licenses, each party has agreed not to challenge the validity or enforceability of the intellectual property licensed to it, subject in each case to certain customary exceptions. Natera retains the right to use alternative sequencing platforms for NIPT; and Natera may narrow the scope of the Natera Licensed IP if as a result Illumina alleges infringement of Illumina's intellectual property.

17:01 EDT Forward Pharma says EP2801355 appeal hearing rescheduled to Feb 2 - Forward Pharma A/S announced that due to current precautionary measures against the spread of the novel coronavirus, the Technical Board of Appeal of the European Patent Office has rescheduled the oral hearing of the appeal against the decision of the Opposition Division that revoked the EP2801355 patent. The new hearing date is February 2, 2021.

16:50 EDT Synnex up 5% to $88.00 after Q2 EPS guidance beats estimates

16:42 EDT Synnex CFO says increased liquidity without raising additional capital - "We have maintained disciplined capital management throughout the pandemic and have increased our liquidity position to nearly $2 billion, without raising additional capital," said Marshall Witt, SYNNEX CFO. "We believe that our strong balance sheet will enhance our ability to successfully navigate through this challenging market backdrop."

16:42 EDT Delta Apparel extends CEO Robert Humphreys contract by two years - Delta Apparel announced a two-year extension of the employment contract with its chairman and CEO, Robert Humphreys. His employment will now expire with the filing of the annual report on Form 10-K for FY22. Humphreys joined the company in 1998 as CEO and became chairman of the board in 2009.

16:38 EDT IsoRay announces CMS approval for 64 Cesium-131 reimbursement billing codes - Isoray announced that the Centers for Medicare and Medicaid Services, or CMS, has approved 64 ICD-10-PCS billing codes used for reimbursement of Cesium-131 for the hospital in-patient DRG setting. The codes allow hospitals to bill Medicare and other health insurers for specific surgical procedures that would benefit from the addition of Cesium-131. DRG or diagnostic related groups are designed for Medicare and other health insurers to set payment levels for hospital in-patient services. The 64 ICD-10-PCS codes are important for the growing surgical applications of Cesium-131 in treating a significant range of hard to treat cancers including brain, lung, head and neck, abdominal, breast, gynecological, pelvic, and colorectal cancers. The new codes take effect on October 1. Isoray is the world's only supplier of Cesium-131. Brachytherapy with Cesium-131 seeds is high energy with a short half-life. Cesium-131's energy is powerful, allowing it to attack the cancer being treated. Its short half-life means the radiation delivers its treatment dose quickly reducing other issues for the patient that can come from prolonged radiation exposure. Unlike external beam radiation, Cesium-131 internal radiation therapy is able to deliver a precise dosage and placement of Cesium-131 seeds avoiding healthy tissues and organs.

16:33 EDT United Natural Foods withdraws FY20 guidance - UNFI is withdrawing its prior fiscal FY20 guidance based on the strength of its FY20 year-to-date financial performance. The Company plans to provide updates to its full year guidance when it reports final Q3 results in early June.

16:29 EDT Allegiant Travel sees Q2 cash burn $2.1M per day, Q3 cash burn $1.5M per day - Cash burn assumes gross bookings for 2Q average $750,000 per day. 3Q cash burn is expected to be $1.5M per day assuming gross bookings average $750,000 per day.

16:23 EDT Vectrus backs FY20 net cash from operating activities $45M-$55M

16:17 EDT Vectrus reports total backlog $4.1B - Total backlog in the quarter ended April 3 was $4.1B and funded backlog was $1.1B. The trailing twelve-month book-to-bill was 1.5x as of April 3. "Backlog grew 48% sequentially to a record $4.1 billion and drove a 1.5x trailing twelve-month book-to-bill ratio," said CFO Lynch. "The size of our backlog is an attractive attribute of our business, representing 2.7 times the midpoint of our 2020 full year revenue guidance, providing visibility into the remainder of the year and beyond."

16:13 EDT Manning & Napier reports preliminary AUM $18B as of April 30 - Compared with $17.1B at March 31.

16:12 EDT Aviat Networks on track to deliver FY20 Adjusted EBitda of $11M-$12M - The company said, "We remain on track to meet our guidance and deliver between $11M-$12M of Adjusted EBITDA this fiscal year, with our eyes set on both top- and bottom-line growth next fiscal year. There are a lot of changes underway now and more to come that should open up new revenue streams and drive profitability which in turn, should lead to increased shareholder value."

16:10 EDT Adaptive Biotechnologies withdraws its previously announced guidance

16:08 EDT Envista is not providing further guidance - As disclosed in a Form 8-K filed April 2, Envista has withdrawn its guidance for 2020 due to the uncertainties surrounding the current operating environment and the unknown duration of the COVID-19 global health pandemic. The Company is not providing further guidance at this time.

16:06 EDT 8x8, Inc, Virgin Media to partner on voice and comms - 8x8, Inc. (EGHT) announced a partnership with Virgin Media Business, in a deal that "will allow Virgin Media Business to extend its Voice and Unified Comms portfolio, providing Public Sector, Enterprise and SME customers with a host of new cloud-based and fully-integrated communications tools from 8x8 covering voice, video, chat and contact centre solutions. Joining forces with 8x8 enables Virgin Media Business to tap into the rapidly growing cloud communications market and provide clients with a single-platform solution. 8x8's unique technology stack offers a whole host of rich features, without the challenges that on-premises equipment often presents, enabling staff to collaborate faster and work smarter wherever they are. The fully global communications platform supports enterprise-class API solutions and allows Virgin Media Business' customers the ability to add new functionality with ease. By moving to cloud based communications services, businesses will be able to reduce their capital expenditure and move towards a future-proof communications platform designed to scale with their business. Under the partnership, Virgin Media Business and 8x8 will work together to configure and rollout integrated cloud services and provide 24/7 support for customers."

16:04 EDT Varex Imaging withdraws FY20 guidance - The company states: "The unprecedented nature of the COVID-19 pandemic and its impact on the global economy has created a disruption to Varex's business which includes significant uncertainty in demand for certain products for medical and industrial applications, as well as increased variability in its supply chain and manufacturing productivity. The company expects this uncertainty to continue for at least the remainder of the current fiscal year. As a result, Varex is withdrawing its previously issued guidance for fiscal year 2020. Further, due to the unpredictability of when and how strong a global economic recovery may be, the company has been implementing actions to reduce its expenses and cash disbursements, some of which were previously disclosed in Varex's Form 8-K dated April 10, 2020. The company continues to evaluate and implement additional cost reduction measures."

15:08 EDT AMC Networks trading resumes

15:03 EDT AMC Networks trading halted, volatility trading pause

14:48 EDT Nikola CEO says VectoIQ merger vote planned for June 2 - Trevor Milton, CEO of Nikola Motor Company, tweeted: "@nikolamotor and $VTIQ Merger vote planned June 2nd! That date can change but it is the expected date as of now. I appreciate everyone who has believed in us. I can't wait for the merger to complete and the ticker to be changed to $NKLA" Reference Link

14:18 EDT Supernus delays filing of quarterly report - In a regulatory filing, Supernus Pharmaceuticals reported that it is unable to file, without unreasonable effort and expense, its Quarterly Report on Form 10-Q for the quarter ended March 31, 2020. The company requires additional time to complete additional documentation regarding the change in estimate on product returns and therefore for the company's independent registered public accounting firm to complete their review procedures on the Form 10-Q. The company does not anticipate any changes to the financial results attached to the Form 8-K filed with the Securities and Exchange Commission on May 7, Supernus noted. It is anticipated that the Form 10-Q will be filed on or before the 5th calendar day following the prescribed due date of the Form 10-Q, the company said.

14:10 EDT Musk twitter thanks Trump for support on factory opening - Tesla CEO Elon Musk said "Thank you!" to President Trump on Twitter for his tweet saying California should let the company open its plant in California "NOW."

14:07 EDT Cushman & Wakefield completes sale of Techwood Business Center - Cushman & Wakefield announced the completed $90,500,000 sale of Techwood Business Center, a six-building, 648,173-square-foot portfolio strategically located in the Baltimore Commons Business Park, one of the most well-established industrial parks in the Corridor. Techwood Business Center's location provides immediate access to the region's transportation arteries (I-95, I-295, I-97) and offers a rare combination of scale and functionality in one of the highest performing supply-constrained markets in the country. "This generational industrial offering received tremendous interest from national and international investors. An e-commerce company emerged as the winning bidder in an extremely competitive sales process due to their strategic interest in this business park and the Baltimore-Washington region," said Jonathan M. Carpenter, executive managing director of Cushman & Wakefield's Baltimore capital markets team.

13:43 EDT Grow with Google launches OnAir for career skills training online - Jesse Haines Director, Grow with Google (GOOG,GOOGL) wrote in an earlier blog post: "Since Grow with Google launched in 2017, we've traveled across all states, from Alaska to Florida, to help Americans get the digital skills they need to succeed. Along the way, we've partnered with local libraries, schools and nonprofits to offer free tools and training to help people get the right skills to find jobs they want, advance their careers and grow their businesses. We've also established a homebase, opening the Grow with Google New York City Learning Center in 2019 to offer free workshops and events to the community six days a week...Today, we're launching Grow with Google OnAir, where Grow with Google's free programming will be online and available to everyone in the U.S. and Canada for the first time. We'll offer digital skills training, interviews with career experts and programming from partners including Merit America and the National Congress of American Indians. Topics will include "How to manage your business remotely in times of uncertainty" and "How to improve your resume with four practical strategies." The Fly notes that Microsoft's (MSFT) Linkedin offers professional development. Reference Link

13:29 EDT GrubHub does not deny Uber takeover talks in statement - In a statement following press reports that Uber Technologies (UBER) approached it with a takeover offer, GrubHub (GRUB) said, "While our policy remains to not comment on specific market rumors, we want to reiterate our views with respect to M&A-related matters given the current level of recent speculation. We remain squarely focused on delivering shareholder value. As we have consistently said, consolidation could make sense in our industry, and, like any responsible company, we are always looking at value-enhancing opportunities. That said, we remain confident in our current strategy and our recent initiatives to support restaurants in this challenging environment." Shares of GrubHub halted for news after jumping 36.5% t $63.87.

13:27 EDT Zillow down over 8% after common stock, convertible debt pans - Shares of Zillow are falling approximately 8% or $4.53 to $51.24 per share in afternoon trading on Tuesday after the online real estate services company announced plans to raise $1B through stock and convertible debt offerings. Zillow announced earlier that it intends to commence a concurrent underwritten public offerings of $500M in shares of its Class C capital stock and $500M aggregate principal amount of its convertible senior notes due 2025.

13:26 EDT GrubHub says 'squarely focused on delivering shareholder value'

13:01 EDT GrubHub trading halted, news pending

12:16 EDT Morgan Stanley to pay $5M penalty to settle SEC charges on retail wrap fees - The Securities and Exchange Commission announced that Morgan Stanley Smith Barney,MSSB, has agreed to settle charges that it provided misleading information to clients in its retail wrap fee programs regarding trade execution services and transaction costs. MSSB has agreed to pay a $5M penalty that will be distributed to harmed investors. Wrap fee programs offer accounts in which clients pay an asset-based "wrap fee" that covers investment advice and brokerage services, including trade execution. According to the SEC's order, MSSB marketed its wrap fee accounts as offering clients professional investment advice, trade execution, and other services within a "transparent" fee structure. From at least October 2012 until June 2017, some of MSSB's marketing and client communications gave the impression that wrap fee clients were not likely to incur additional trade execution costs. During that period, however, the order finds that some MSSB managers routinely directed wrap fee clients' trades to third-party broker-dealers for execution, which in some instances resulted in MSSB clients paying additional transaction fees that were not visible to them. As a result of MSSB's conduct, the order finds that certain MSSB clients were unable to assess the value of the services received in exchange for the wrap fee paid to MSSB. "Investment advisers are obligated to fully inform their clients about the fees that clients will pay in exchange for services," said Melissa R. Hodgman, Associate Director in the SEC's Division of Enforcement. "The SEC's order finds that Morgan Stanley Smith Barney failed to provide certain clients in its retail wrap fee programs accurate information about the costs they incurred for the services they received."Reference Link

12:09 EDT Waitr Holdings jumps about 20% following reports on GrubHub talks with Uber - Shares of Waitr Holdings (WTRH) are up 57c, or 18%, to $3.68 after Bloomberg and The Wall Street Journal each reported that Uber Technologies (UBER) has made an offer to acquire rival food delivery service GrubHub (GRUB). Waitr, like GrubHub and Uber Eats, competes in the food delivery space.

12:03 EDT Veru gets FDA agreement to begin Phase 2 study of VERU-111 for COVID-19 - Veru announced that it has received FDA permission to initiate a Phase 2 clinical trial to assess the efficacy of VERU-111, a microtubule depolymerization agent, in combating COVID-19, the global pandemic disease caused by the novel coronavirus SARS-CoV-2. VERU-111 is an oral, first-in-class microtubule depolymerization agent that targets the colchicine binding site of a and b tubulin subunits to inhibit microtubules and is currently under clinical development in prostate cancer. Drugs that target microtubules have broad antiviral activity by disrupting the intracellular transport of viruses such as SARS CoV-2, along microtubules. Microtubule trafficking is critical for viruses to cause infection. Furthermore, microtubule depolymerization agents that target a and b tubulin subunits of microtubules also have strong anti-inflammatory effects including the potential to treat the cytokine release syndrome, cytokine storm, induced by the SARS-CoV-2 viral infection that seems to be associated with high COVID-19 mortality rates. The Company met with FDA and received agreement on the clinical development program for VERU-111 as a potential dual antiviral and anti-inflammatory agent to combat COVID-19 under the new FDA program--Coronavirus Treatment Acceleration Program, CTAP. The Phase 2 clinical trial is a double-blind randomized (1:1) placebo-controlled trial evaluating daily oral doses of VERU-111 versus placebo for 21 days in 40 hospitalized patients (VERU-111 20 subjects and placebo 20 subjects) who tested positive for the SARS-CoV-2 virus and are at high risk for Acute Respiratory Distress Syndrome (ARDS). The primary efficacy endpoint will be the proportion of patients that are alive and without respiratory failure at Day 29. Secondary endpoints include the measured improvements on the WHO Disease Severity Scale which captures COVID-19 disease symptoms and signs including hospitalization to progression of pulmonary symptoms to mechanical ventilation as well as death. The study is expected to commence in the next 2 weeks.

12:00 EDT Eventbrite falls -20.2% - Eventbrite is down -20.2%, or -$2.13 to $8.40.

12:00 EDT Lydall rises 23.0% - Lydall is up 23.0%, or $2.50 to $13.35.

12:00 EDT GrubHub rises 25.8% - GrubHub is up 25.8%, or $12.07 to $58.86.

11:12 EDT Luckin Coffee terminates CEO, COO following internal investigation - Luckin Coffee announced changes to its Board of Directors and senior management, effective May 11, 2020. During its ongoing internal investigation, the Special Committee of the Board has brought to the attention of the Board evidence that sheds more light on the fabricated transactions described in the press release issued by the Company on April 2, 2020. After considering such information, the Board has terminated Ms. Jenny Zhiya Qian and Mr. Jian Liu from the positions of the CEO and the COO, respectively. The Board also demanded and received from Ms. Qian and Mr. Liu their resignations from the Board. In addition to Ms. Qian and Mr. Liu, since the beginning of the Internal Investigation, the Company has placed six other employees, who were involved in or had the knowledge of the fabricated transactions, on suspension or leave. The Board has appointed Mr. Jinyi Guo, a director to the Board and a SVP of the Company, as the Acting CEO of the Company. The Board also announced the appointment of Mr. Wenbao Cao and Mr. Gang Wu as directors to the Board. Following the changes to the Board, the Compensation Committee of the Board currently consists of Mr. Sean Shao, Mr. Erhai Liu and Mr. Jinyi Guo, with Mr. Sean Shao serving as its chairman; the Nominating and Corporate Governance Committee of the Board currently consists of Mr. Wai Yuen Chong, Mr. David Hui Li and Mr. Jinyi Guo, with Mr. Wai Yuen Chong serving as its chairman; the composition of Audit Committee of the Board remains unchanged.

11:01 EDT Luckin Coffee names Jinyi Guo as acting CEO

11:00 EDT Luckin Coffee terminates CEO Jenny Zhiya Qian, COO Jian Liu - In a regulatory filing, Luckin Coffee said "During its ongoing internal investigation, the Special Committee of the Board has brought to the attention of the Board evidence that sheds more light on the fabricated transactions described in the press release issued by the Company on April 2, 2020. After considering such information, the Board has terminated Jenny Zhiya Qian and Jian Liu from the positions of the CEO and the COO, respectively. The Board also demanded and received fromQian and Liu their resignations from the Board. In addition to Qian and Liu, since the beginning of the Internal Investigation, the Company has placed six other employees, who were involved in or had the knowledge of the fabricated transactions, on suspension or leave.The Board has appointed Mr. Jinyi Guo, a director to the Board and a Senior Vice President of the Company, as the Acting Chief Executive Officer of the Company. The Board also announced the appointment of Mr. Wenbao Cao and Mr. Gang Wu as directors to the Board. Following the changes to the Board, the Compensation Committee of the Board currently consists of Sean Shao, Erhai Liu and Jinyi Guo, with Sean Shao serving as its chairman; the Nominating and Corporate Governance Committee of the Board currently consists of Wai Yuen Chong, David Hui Li and Jinyi Guo, with Wai Yuen Chong serving as its chairman; the composition of Audit Committee of the Board remains unchanged. Wenbao Cao has served as Senior Vice President of the Company in charge of store operations and customer service since June 2018. Before joining the Company, Cao had over 23 years of experience at McDonald's China and served in various positions, including vice president and North regional manager at McDonald's China."

10:55 EDT GrubHub trading halted, volatility trading pause

10:32 EDT MoneyGram reports digital business transactions grew 81% year-over-year in April - MoneyGram International reported 81% year-over-year transaction growth for its digital business in April - an acceleration from the first quarter of 2020 where the company reported 57% transaction growth. "These strong trends have also continued into May," the company stated. "We've been on a mission to mobilize the movement of money and accelerate the evolution of digital P2P payments. Over the last few years, we've invested heavily in our digital transformation by building the best digital customer experience in the industry and then rapidly launching those capabilities to new markets. We're proud that these investments have enabled customers to continue sending money for life's daily needs as global shelter-in-place policies have disrupted everyday life as we all work to prevent the spread of COVID-19," added Alex Holmes MoneyGram Chairman and CEO.

10:03 EDT Roche announces launch of new KAPA Target Enrichment portfolio - Roche announced the launch of the new KAPA Target Enrichment portfolio, consisting of both exome and custom target enrichment solutions for sequencing. "KAPA HyperExome is a whole exome research panel with significantly improved performance over the existing on-market SeqCap portfolio and other products on the market. In addition to the Target Enrichment portfolio, Roche is also launching the new HyperDesign tool that enables researchers to create custom target enrichment designs that utilize the new KAPA HyperChoice probes. The probes are paired with a streamlined, automatable workflow," the company said.

10:00 EDT Eventbrite falls -13.0% - Eventbrite is down -13.0%, or -$1.36 to $9.16.

10:00 EDT Clipper Realty rises 20.0% - Clipper Realty is up 20.0%, or $1.02 to $6.13.

10:00 EDT Lydall rises 22.6% - Lydall is up 22.6%, or $2.46 to $13.31.

09:47 EDT Sequans falls -10.9% - Sequans is down -10.9%, or -65c to $5.28.

09:47 EDT Cherry Hill Mortgage rises 12.5% - Cherry Hill Mortgage is up 12.5%, or 79c to $7.07.

09:47 EDT Vedanta rises 22.6% - Vedanta is up 22.6%, or 94c to $5.07.

09:39 EDT MGM Resorts to 'strongly encourage' guests to wear masks in public areas - MGM Resorts released a report outlining the comprehensive health and safety protocols the company is implementing prior to re-opening its domestic properties and resorts which were temporarily closed in March due to the COVID-19 pandemic. The report details MGM Resorts' "Seven-Point Safety Plan" - a multi-layered set of protocols and procedures designed in conjunction with medical and scientific experts to deter the spread of the virus, protect customers and employees and rapidly respond to potential new cases. MGM Resorts is working with Dr. Shannon Magari, ScD, MPH, MS as its lead health and safety advisor for this process. Dr. Magari is the Vice President of Health Sciences for Colden Corporation, an occupational health, safety and environmental firm. The company said, "These protocols and procedures focus on balancing the customer service guests have come to expect from MGM Resorts with the urgent need to apply knowledge about COVID-19 and adapt environments accordingly. This plan is being implemented at MGM Resorts properties throughout the United States, with additions and changes being made based on local jurisdictions. Screening, Temperature Checks and Employee Training: MGM Resorts has implemented employee-screening measures to assess signs and symptoms of infection and whether the employee resides or cares for someone who has recently been diagnosed with the virus. Employees are currently and will continue to go through temperature checks before entering properties. Guests will be asked to abide by a similar self-screening protocol prior to arriving and during their stay... andatory Masks and Personal Protective Equipment : All MGM Resorts employees will be provided and required to wear an approved mask when on our properties. We will also strongly encourage guests to wear masks in public areas and offer masks to any guests who need one, free of charge. Gloves will continue to be worn by employees who require them to do their jobs, such as food handlers and employees who clean public areas. Additional categories of employees required to wear PPE will be identified by medical experts. Drink service: We will ask guests to minimize the amount of time masks are removed when drinking on the casino floor. Eating: We will ask guests to refrain from eating on the casino floor to minimize the amount of time masks are removed. Physical Distancing: Six-foot physical distancing policy will be in place, wherever feasible, with floor guides serving as reminders throughout MGM Resorts properties. From time-to-time, six-foot distancing will be challenging - and in those cases, reasonable mitigating protocols will be implemented, such as plexiglass barriers or eye protection for employees. Plexiglass barriers will be installed in areas throughout casinos and lobbies, where appropriate, for the safety of guests and employees. Signage will be installed throughout properties to guide employees and guests on how to safely practice physical distancing. Handwashing and Enhanced Sanitization: Prior to property closures in March, MGM Resorts implemented increased and enhanced routine cleaning, based on CDC guidelines, with a focus on high touch surfaces in common areas. We will continue using proven cleaning products in accordance with EPA guidelines for coronaviruses, bacteria and other infectious pathogens. Electrostatic sprayers will be used in many large areas to allow us to apply disinfectant more efficiently. In addition, custom-built handwashing stations with soap and water, along with hand-sanitizing stations, will be readily available in high traffic areas and with a visible presence. Signage will be installed to guide and remind employees and guests of the importance of proper handwashing protocols. Heating Ventilation and Air Conditioning Controls and Air Quality: MGM Resorts has always placed a high priority on air quality for our guests and has reviewed the operation of HVAC systems to identify additional opportunities to enhance their effectiveness. Rigorous measures in accordance with established guidelines to help mitigate the risk of virus transmission have been taken throughout our properties... Incident Response Protocols: MGM Resorts has protocols in place aimed at reducing the chance infection will spread. In the unfortunate event a guest or employee tests positive for the virus, we will activate incident response protocols to ensure the infected individual has access to medical treatment, exposed areas are thoroughly sanitized and, when possible, notify those who may have come in close, prolonged contact with the infected individual... Digital Innovations: MGM Resorts is reimagining several aspects of the guest experience through technology to transition current processes into contactless options for guests that eliminates or reduces the need for waiting in line. Contactless Check-In: Guests will have the ability to complete the check-in process entirely themselves through the MGM Resorts mobile app. This includes the ability to process payment, verify identification and obtain a digital room key, all through a mobile device...Food & Beverage: Digital menus will be available to view on personal mobile devices via QR code. Virtual queues will be in place for guests when immediate seating is unavailable."

09:37 EDT Pulse Biosciences trading resumes

09:33 EDT ToughBuilt launches 81 products with Tractor Supply - ToughBuilt Industries (TBLT) announced that 81 SKUs of its products have been accepted for immediate placement on www.tractorsupply.com (TSCO). Additionally, the Company is launching an in-store promotion of four SKUs with Tractor Supply brick and mortar stores.

09:31 EDT Natus Medical partners with Holberg EEG to advance epilepsy diagnosis - Natus Medical announced a partnership with Holberg EEG AS. The partnership will advance the development and distribution of an AutoSCORE algorithm to automate Electroencephalography classifications and improve reporting efficiency. Holberg EEG has developed and commercialized SCORE EEG, a reporting and database software that builds on the new international consensus for describing EEG examinations and replaces free text reporting. The new partnership will advance the next steps to develop AutoSCORE, which will provide decision support to reduce EEG reporting variability, improve quality, and reduce time and cost for users. AutoSCORE has the potential to improve clinical outcome and value of care for the millions suffering from epilepsy.

09:13 EDT AeroVironment awarded $2.69M contract from U.S. ally - AeroVironment announced that a U.S. ally and longtime customer awarded the company a firm-fixed-price contract valued at $2.69M on February 20, 2020 for AeroVironment's recently introduced Puma LE. The order also included spares to support the customer's existing fleet of AeroVironment tactical UAS. The contract award period of performance is one year.

09:08 EDT ShiftPixy unveils free digital restaurant solution to support restaurants - ShiftPixy announced that as part of its recently introduced Restaurant Resilience Plan, its technology platform specifically designed for restaurants is now available for free, without initial investment, to help restaurant operators and entrepreneurs as they face the unprecedented impacts of the COVID-19 crisis. Offering a digital platform that manages everything from online ordering through to native delivery driver management, ShiftPixy is making its technology more readily available so that restaurants can focus on doing what they do best - offering a great food experience. In addition to the free implementation of its platform, ShiftPixy also offers HNOA insurance to each of its delivery tickets to further ease the struggles of restaurants shifting to a delivery-first environment. Further, ShiftPixy is waving all delivery fees throughout the crisis.

09:06 EDT Ria Money Transfer launches Money Transfer App across Europe - Ria Money Transfer announced the release of its Ria Money Transfer App for the European market with plans to launch in 13 countries by June. The first wave of releases began this month with the app launching in France and Germany. Italy, Belgium, Netherlands, Luxembourg, Austria, Ireland, Denmark, Finland, Norway, Sweden, and Switzerland will follow suit during May. Outside of Europe, the app is available in the United States and Canada. Australia, the UK, and Spain also offer online money transfer services via riamoneytransfer.com. Ria's digital footprint also includes the largest bank deposit network in the world with access to over three billion bank accounts.

09:04 EDT Datadog partners with Auth0 for identity data in near real-time - Auth0, the identity platform for application builders, today announced that it has partnered with Datadog to provide security, engineering, and infrastructure teams with mission-critical identity information in near real-time. The integration is powered by Auth0's new log streaming capabilities, giving customers the ability to continuously deliver Auth0 logs to their existing monitoring and alerting dashboards, making operations easier and more effective.

09:02 EDT Cellect Biotechnology announce exercise of warrants for cash proceeds of $1.5M - Cellect Biotechnology announced the agreement by several investors to exercise certain warrants issued in February 2019 to purchase up to an aggregate of 534,160,000 ordinary shares represented by 534,160 American Depositary Shares having an original exercise price of $7.50 per ADS, at a reduced exercise price of $2.75 per ADSs. Simultaneously with entry into these agreements the Company determined to lower the exercise price of all outstanding warrants issued in February 2019 with an original exercise price of $7.50 to $2.75 per share. The ADSs and the ordinary shares issuable upon exercise of the warrants are registered pursuant to a registration statement on Form F-1, which became effective by the Securities and Exchange Commission on February 7, 2019, as supplemented and amended to date. The gross proceeds to Cellect from the exercise of the warrants are expected to be approximately $1.5 million, prior to deducting placement agent fees and estimated offering expenses. Cellect intends to use the net proceeds from the offering for working capital as well as other general corporate purposes.

08:55 EDT Dolby introduces Dolby.io API platform - Dolby Laboratories announced Dolby.io, an API platform that further broadens the opportunities to create in Dolby for the enterprise and application development space. Dolby.io will enable businesses, developers, and content creators to enhance every interaction and every piece of content in order to deliver spectacular communications, collaboration, and audiovisual experiences in their apps and services.

08:53 EDT AquaBounty engages MZ Group to lead investor relations program - AquaBounty Technologies has engaged investor relations specialists MZ Group to expand its comprehensive strategic investor relations and financial communications program. MZ Group will work closely with the management of AquaBounty to develop and implement a comprehensive capital markets strategy designed to increase the Company's visibility throughout the investment community. AquaBounty's investor relations campaign will highlight its disruptive and proprietary technology in the farmed salmon industry, as well the Company's imminent commercial harvests of both conventional Atlantic salmon in June 2020 and AquAdvantage salmon in the fourth quarter of 2020. MZ Group has developed a distinguished reputation as a premier resource for institutional investors, brokers, analysts and private investors. The firm maintains offices worldwide, including New York, Chicago, Minneapolis, San Diego, Aliso Viejo, Austin, Taipei and Sao Paulo. Additionally, MZ Group was recently ranked the No. 1 consultancy in Latin America and No. 7 in the world in business communication. Greg Falesnik, Managing Director of MZ North America, will advise AquaBounty in all facets of corporate financial communications, including the coordination of roadshows and investment conferences in key cities worldwide and building brand awareness across all financial and media outlets.

08:50 EDT Dave & Buster's appoints John Hockin to board of directors - Dave & Buster's Entertainment announced that John C. Hockin has been appointed to the Company's Board of Directors, effective May 8, 2020. Mr. Hockin is a Managing Director at KKR, a leading investment firm with significant holdings in both private and public equities. With this appointment, the Company is temporarily expanding the size of its Board to 10 members. Victor Crawford, who has served on the Board since 2016, has decided not to stand for re-election at the Company's upcoming Annual Meeting of Shareholders. As such, at the Annual Meeting the Board will automatically be reduced back to nine directors, seven of whom will be independent.

08:49 EDT Evoke Pharma expects cash to support operations into 3Q20 - As of March 31, 2020, the Company's cash and cash equivalents were approximately $4.1 million. The Company expects that its current cash balance will be sufficient to support operations into the third quarter of 2020, excluding the Eversana line of credit of $5 million that will become available if FDA approves Gimoti.

08:45 EDT Newater Technology Inc trading resumes

08:42 EDT CACI awarded $465M task order by U.S. Army - CACI announced that it has been awarded a five-year single-award task order, with a ceiling value of more than $465M, by the U.S. Army Combat Capabilities Development Command's, or CCDC, Command, Control, Computers, Communications, Cyber, Intelligence, Surveillance, and Reconnaissance, or C5ISR, center to provide research and development on cryptographic modernization, information security, and tactical network protection. Under the task order, which the Army's Cyber Security and Information Division, or CSIA, awarded under the GSA Alliant II contract vehicle, CACI will provide mission expertise to enhance cyber defense capabilities for C5ISR systems. CSIA leads the Army in cryptographic modernization, information security, and tactical network protection as a division of the Army Space and Terrestrial Communications Directorate, C5ISR Center, CCDC, U.S. Army Futures Command, or AFC. CACI will provide the Army with new software-defined capabilities across the service's many modernization initiatives and research areas. For example, CACI communications and cyber experts will assist the service in protecting next-generation 5G networks, as well as enhancing the security of wireless, near-field, satellite, and other communications. CACI will also support urgent requirements for AFC's cross-functional teams, provide techniques and technologies to reduce risks for Army networks, and move innovative technologies such as artificial intelligence from the laboratory to the field.

08:41 EDT Hancock Jaffe Laboratories to conduct CoreoGraft bioprosthetic graft study - Hancock Jaffe Laboratories announced that the company has received approval from the superintendent of Health of the National Health Counsel for the Republic of Paraguay to conduct a first-in-human study for its CoreoGraft bioprosthetic graft. The first-in-human study will initially consist of five patients who will receive CoreoGrafts as part of their coronary artery bypass graft, or CABG, surgeries. The CoreoGraft patients will be monitored for a one-year period post CoreoGraft surgery, with interim results reported at 30, 90, 180 and 365 days. Enrollment for the first-in-human study will begin as soon as COVID-19 restrictions are lifted in Paraguay.

08:40 EDT IntelGenx announces intention to amend convertible debentures - IntelGenx Technologies announced that it is proposing to amend the terms of its 8.0% convertible unsecured subordinated debentures due June 30, 2020, originally issued on July 12, 2017 and August 8, 2017 (the "Debentures"), to extend the maturity date from June 30, 2020 to June 30, 2022 and reduce the conversion price from $1.35 to $0.50. The proposed amendments remain subject to approval of the TSX Venture Exchange and the holders of not less than 66 2/3% of the outstanding principal amount of the Debentures. An aggregate principal amount of $7,577,000 of Debentures remains outstanding as of the date hereof.

08:38 EDT Jaguar Health clears regulatory hurdle to gain FDA approval to market Canalevia - Jaguar Health announced that it has cleared an important regulatory hurdle in the company's effort to gain FDA approval to market Canalevia, the company's oral plant-based prescription drug candidate, for the treatment of exercise-induced diarrhea, or EID, in dogs. Jaguar has been informed by the FDA's Center for Veterinary Medicine, or CVM, that the Environmental Impact technical section has been deemed Complete as part of the Company's application for conditional approval of Canalevia for EID under the Minor Use/Minor Species, or MU/MS, section of The Minor Use and Minor Species Animal Health Act of 2004. This section provides an assessment of a drug's potential direct and indirect effect on the environment.

08:37 EDT Alkaline Water says German grocery chain sells Alkaline88 across U.S. stores - The Company announces that one of the world's largest grocery chains expanding into the U.S. is selling two SKUs of its flagship brand across its stores.

08:36 EDT Enzo Biochem issued U.S. patent for methods of producing monoclonal antibodies - Enzo Biochem announced the recent issuance of U.S. Patent No. 10,626,170 entitled Sulfonated Sclerostin, Antibodies, Epitopes and Methods for Identification and Use Therefor. The patent is directed to methods for producing monoclonal antibodies against specific regions of human Sclerostin, a protein that is a negative regulator of bone growth. Inhibition of Sclerostin using monoclonal antibodies can be used to promote bone growth for the treatment of osteoporosis. U.S. Patent No. 10,626,170 is a member of a broader U.S. and international patent family that includes issued patents and pending patent applications directed to antibodies and their use in inhibiting Sclerostin as well as small synthetic peptides and their use in inhibiting Sclerostin in the treatment of bone disorders such as osteoporosis.

08:35 EDT Phathom developing plans to resume new patient randomization in trials - During the first quarter of 2020, Phathom temporarily paused new patient randomization in its PHALCON-EE and PHALCON-HP clinical trials. The decision was not based on any study-related COVID-19 infections or other safety events but rather in support of global efforts to combat the SARS-CoV-2 coronavirus. Phathom has been actively working with clinical trial sites to ensure uninterrupted clinical trial supply, support the continuation of patients who were already enrolled in the PHALCON-EE and PHALCON-HP trials prior to the randomization pause, and develop plans to resume new patient randomization. Phathom is monitoring the continuing evolution of the COVID-19 pandemic, and any decision to allow randomization of new patients at a site will be contingent on a number of factors including restrictions imposed by national, state, and local governments as well as ASGE guidelines and other prevailing professional guidelines.

08:32 EDT Homology Medicines announces presentations on in vivo gene therapy, gene editing - Homology Medicines announced the presentation of data at the American Society of Gene & Cell Therapy 23rd Annual Meeting. Among Homology's seven presentations are data from its in vivo nuclease-free gene editing program for phenylketonuria and in vivo gene therapy program for metachromatic leukodystrophy, both of which are in IND-enabling studies. Presentations also focus on the Company's commercial manufacturing platform, as well as data on the differentiating characteristics of Homology's family of AAVHSC vectors, particularly when compared to other AAVs, which highlight the potential of the Company's dual gene therapy and editing platform. The presentation, "Molecular Characterization of Precise In Vivo Targeted Gene Editing in Human Cells using AAVHSC15, a New AAV Derived from Hematopoietic Stem Cells," describes quantitative molecular methods to measure efficiency and precision of nuclease-free, homologous recombination-based gene editing. The studies, which used a single I.V. administration of a gene editing construct to insert the human PAH gene, which is mutated in people with phenylketonuria in a humanized liver murine model, show: Precise gene editing with no unintended on-target mutations or viral integration, supportive of the homologous recombination pathway. Six percent gene editing efficiency using two independent molecular assays. This level of editing is an improvement over the efficiencies published in others' nuclease-free gene editing studies, and it has been shown to be sufficient to normalize Phe levels in the murine model. Two posters related to Homology's internal commercial manufacturing platform will be presented. In "Molecular Design and Characterization of Packaging Plasmid Sequences for Improved Production of Novel Clade F AAVHSCs," the data demonstrate: AAVHSCs were suitable for packaging a wide range of AAV genome sizes and yielded more intact packaged genomes than AAV5, a non-Clade F serotype. Improved productivity and optimized upstream process following enhancements to the packaging plasmid sequences. In "Development and Scalability of Transfection-Based Production and Purification of Novel Clade F Adeno-Associated Viruses Isolated from Human Hematopoietic Stem Cells". Homology describes high-quality productivity and scalability of its mammalian, suspension-based manufacturing, including: Executed 2,000-liter bioreactor scale using Homology's commercial process, with comparable productivity and product quality to smaller scale runs. Improved product quality using anion exchange purification, which can be leveraged across Homology's family of AAVHSC vectors and product candidates. Related to Homology's HMI-202 investigational gene therapy for MLD, the presentation, "Gene Therapy for Metachromatic Leukodystrophy That Crosses the Blood-Nerve and Blood-Brain Barriers in Mice and Non-Human Primates," details that a single I.V. administration: Crossed the blood-brain-barrier and blood-nerve barriers in the MLD murine model and in non-human primates, with human ARSA enzyme detected in both species. Showed hARSA biodistribution in the murine model that resembled endogenous murine ARSA in age-matched controls. Produced durable hARSA levels in the murine model meeting or exceeding normal human brain ARSA activity levels out to 52 weeks. Positively impacted key MLD biomarkers, including reducing sulfatides and LAMP-1, as well as increased MAL. In collaboration with Children's Hospital of Philadelphia, Homology also presents, "In Vivo Transduction of Murine Hematopoietic Stem Cells after Intravenous Injection of AAVHSC15 and AAVHSC17," which shows: AAVHSC15 and AAVHSC17 - two of Homology's family of 15 AAVHSCs that were tested in the studies - can target murine hematopoietic stem cells in vivo. Transduced cells were viable, self-renewed and actively contributed to hematopoiesis over time As Homology has advanced its AAVHSC technology, it is presenting mechanistic data on the platform, including the following two presentations. In "Role of Terminal Galactose in Cellular Uptake, Intracellular Trafficking, and Tissue Tropism Using Adeno-Associated Viruses Isolated from Human Stem Cells," the data show: AAVHSC transduction efficiency improved with increased galactose binding, a finding that has been previously described with Clade F vector AAV9. Nucleotide differences in AAVHSCs led to differences in transduction efficiencies related to galactose binding. In "AAVHSCs Transduction Does Not Significantly Elicit p53-Mediated Apoptosis or Alter Cell Cycle in Human iPSCs and Primary Cells When Compared to Non-Clade F AAV Vectors," the studies demonstrate that AAVHSCs: Have differentiating properties than those vectors in Clades 1-8, and did not induce p53 or CHK2 activation, which are responsible for apoptosis. Even at high multiplicities of infection, AAVHSCs did not elicit cell death or alter cell cycle.

08:28 EDT Marathon Patent Group purchases 660 S19 Pro ASIC Miners - Marathon Patent Group announced the purchase of an additional 660 latest generation Bitmain S19 Pro Miners. The 660 miners produce 110 TH/s and will generate 73 PH/s of hashing power, bringing the company's total Hashrate to 129 PH/s compared to companies S-9 production of 46 PH/s. The company paid $1,729,200 and the purchase was funded with cash on hand. The company expects to take delivery at our Hosting Facility by the end of July and will be deployed by our hosting partner Compute North upon their arrival. On May 11, 2020, Marathon announced its purchase of 700 M30S+ miners. The combined purchase is another step supporting the Company's recent strategic initiatives focused on expanding its bitcoin mining operations. Marathon anticipates that the 700 M30S+ miners will be deployed by June 1, 2020 and the S19 Pro's in late July. When all 1,360 miners are fully deployed, Marathon estimates its aggregate operating hash rate will increase over 280% to approximately 129 petahash per second. The latest generation of bitcoin Application-Specific Integrated Circuit miners from Bitmain are markedly more energy efficient than prior Bitmain models and other ASIC miners currently available. The May 11th purchase of 660 Bitmain S19 Pro Antminers boast a hash rate of 110 TH/s and an energy efficiency of 29.5+/-% 5 joules per terahash.

08:26 EDT Kratos Defense receives $14M C5ISR system award - Kratos Defense & Security Solutions announced that it has received a $14 million Command, Control, Communication, Computing, Combat, Intelligence, Surveillance and Reconnaissance System award. Kratos is a leading provider of C5ISR Systems and Solutions in support of Unmanned Aerial Drone, Missile, Radar, Missile Defense, High Powered Directed Energy and Chemical, Biological, Radiation, Nuclear and Explosive Detection Programs for National Security Missions. The C5ISR systems under this contract award will be produced in secure Kratos manufacturing facilities. Due to competitive, customer related and other considerations, no additional information will be provided related to this contract award.

08:23 EDT OraSure consolidates microbiome services subsidiaries - OraSure Technologies announced that its Diversigen and CoreBiome subsidiaries have combined their microbiome service offerings under the Diversigen name. The rebrand highlights the combined companies' unparalleled scientific bench strength, state-of-the-art laboratory, ability to translate data to insights and collective focus on quality and service. The unified Diversigen operation will continue to offer the science-driven, customized solutions for metagenomics sequencing, bioinformatics, and statistical analysis for the study of the microbiome for which CoreBiome and Diversigen are known. The unification elevates Diversigen as the cornerstone brand for microbiome services in the industry. The combined organization includes scientific experts representing more than a century of microbiome experience and over 300 articles in respected scientific publications with more than 100,000 citations. All services previously offered under the CoreBiome brand will continue to be available from Diversigen, offering the microbiome market unparalleled choice in sequencing, bioinformatics and analysis services. The rebrand was implemented after in-depth research, market analysis, and customer conversations. A new Diversigen logo will bring a sharp new visual identity, representing the best of both CoreBiome and Diversigen and characterizes the brand as smart, market-driven, and innovative.

08:21 EDT Nokia announces collaboration with Microsoft as part of SONiC initiative - Nokia (NOK) announced its collaboration with Microsoft (MSFT) as part of the SONiC initiative, an open source network operating system based on Linux that has been production-hardened in the data centers of some of the largest cloud-service providers. Leveraging over 20 years of experience building some of the world's largest IP networks, Nokia has developed a robust chassis-based SONiC implementation focused on the requirements of high capacity data centers. Nokia is strongly committed to delivering the most robust network infrastructures possible with a keen focus on resilient and efficient operations at scale.

08:20 EDT STMicroelectronics publishes annual sustainability report - STMicroelectronics announced the publication of its 2020 Sustainability Report. The 23rd report contains details and highlights of STM's sustainability performance in 2019 and presents the Company's ambitions and longer-term goals for 2025 in alignment with the United Nations Global Compact1 Ten Principles and Sustainable Development Goals. The company said, "2019 highlights included: Delivered net revenues of $9.56 billion, an operating margin of 12.6%, and invested 15.7% of revenues in R&D to support innovation; Reached 62% of new products classified as 'responsible', an increase of 24% compared to 2018, in the framework of our Sustainable technology program launched in 2011; Strengthened our supplier audit program with the RBA2 standard and methodology deployed across our supply chain in order to engage them in doing business responsibly; 99% of new suppliers screened on social and environmental criteria; and Included in the Dow Jones Sustainability Indices World and Europe. Continued to promote employee health and well-being; conducted 97,715 medical acts worldwide vs 87,742 in 2018; Enrolled more than 8,000 human resources staff and managers in a Diversity and Inclusion awareness training program in 2019; Covered 100% of our 11 main manufacturing sites with RBA audits, all scores above the industry average; Strengthened our STEM3 program for inspiring the next generation with 83% of our community initiatives dedicated to education; and Increased our engagement score in 2019 with 77% of our employees recommending ST as a great place to work. Accelerated our efforts to address climate change challenges and achieved our goal of reducing our GHG emissions per unit of production by 21% compared to 2016, six years ahead of our 2025 goal; Engaged in the clean energy transition using more green energy in our manufacturing operations, 26% of the electricity we purchased in 2019 came from green sources; Succeeded in reducing our overall water footprint by 76% over the last 25 years, and received a B score in the CDP4 water security in 2019, positioning ST higher than the average for the electrical and electronic equipment sector and the global CDP average; and Reused, recovered, or sent for recycling 94% of our waste, remaining on track to reach our goal of 95% by 2025."

08:18 EDT Privet, UPG send letter to Synalloy stockholders regarding board nominees - Privet and UPG Enterprises, which collectively own approximately 24.9% of the outstanding common stock of Synalloy, sent a letter to stockholders in connection with their nomination of five candidates for election to the company's eight-member board at Synalloy's upcoming 2020 annual meeting of stockholders scheduled to be held on June 30. Privet and UPG are urging stockholders to vote on the white proxy card to elect its entire slate: Andee Harris, Chris Hutter, Aldo Mazzaferro, Ben Rosenzweig and John Schauerman.

08:16 EDT BioNTech expects to initiate Phase 1/2a trial of BNT411 in 1H20

08:16 EDT Moderna receives FDA Fast Track designation for mRNA-1273 against coronavirus - Moderna announced that the FDA has granted Fast Track designation for the company's mRNA vaccine candidate (mRNA-1273) against the novel coronavirus (SARS-CoV-2). Moderna has received initial feedback from the FDA on the design of the planned Phase 2 study, which will evaluate the safety, reactogenicity and immunogenicity of two vaccinations of mRNA-1273 given 28 days apart. The company intends to enroll 600 healthy participants across two cohorts of adults ages 18-55 years and older adults ages 55 years and above. Each participant will be assigned to receive placebo, a 50 microgram or a 250 microgram dose at both vaccinations. Participants will be followed through 12 months after the second vaccination.

08:15 EDT BioNTech expects data update for Phase 1/2 BNT131 trial in 2H20

08:14 EDT BioNTech expects data update for Phase 1 BNT122 trial in June 2020

08:13 EDT BioNTech expects to initiate Phase 2 trial of BNT113 in 2H20

08:12 EDT BioNTech expects to initiate Phase 2 trial of BNT111 in 2H20

08:12 EDT BioNTech says has potential to supply millions of vaccine doses by year-end - BioNTech will provide clinical supply of the BNT162 vaccine from its GMP-certified mRNA manufacturing facilities in Europe. BioNTech and Pfizer will work together to scale-up manufacturing capacity at risk to provide worldwide supply in response to the pandemic. BioNTech believes it has the potential to supply millions of vaccine doses by the end of 2020 subject to technical success of the development program and approval by regulatory authorities, and then rapidly scale up capacity to produce hundreds of millions of doses in 2021.

08:10 EDT BioNTech continues to monitor effect of COVID-19 pandemic - BioNTech continues to monitor the effect of the current COVID-19 pandemic situation on its overall operations. As previously announced, the company has put significant measures in place to protect supply chain, operations, employees and the execution of clinical trials. The Company has not seen any impact on its mRNA manufacturing, nor on its CAR-T manufacturing operations. BioNTech has implemented a plan to manage the evolving disruptions on the Company's clinical programs, and as previously detailed, is prioritizing execution of ongoing clinical trials, whereas certain first-in-human clinical trial timelines have been affected. BioNTech intends to initiate Phase 2 trials planned for end of 2020, manage ongoing Phase 1 trials to support completion and optimize ability to initiate and conduct FIH studies. BioNTech will continue to evaluate potential effects and provide updates as appropriate.

08:07 EDT HC2 Holdings completes sale of interest in HMN joint venture - HC2 Holdings announced that the Company, through an indirect subsidiary in which HC2 holds an approximate 73% equity interest, has completed the first close of the sale of its 30% stake in Huawei Marine Networks Co., Limited, its 49%-owned equity investment, to Hengtong Optic-Electric Co. The transaction concludes the sale process that was announced in October 2019. The 30% interest was sold for $85 million. After taxes and transaction fees, HC2's portion of the total net proceeds will be used to redeem over $50 million of HC2's 11.5% Senior Secured Notes at a redemption price of 104.5% of the principal amount in June 2020. The remaining 19% interest will be held by the Company subject to a two-year put option.

08:06 EDT Daseke appoints Rick Williams as EVP, COO - Daseke announced that it has named Rick Williams as the Company's EVP and COO. In this new executive role, Mr. Williams will be responsible for managing Daseke's scale in the flatbed and specialized trucking market, and further leveraging the Company's scale into profitable earnings growth. Additionally, Mr. Williams will be responsible for overseeing ongoing business integrations and further business optimization efforts across the portfolio. In September 2019, Mr. Williams was named Flatbed Segment Division Head, where he was primarily responsible for overseeing and implementing best practices across the Daseke Flatbed Segment.

08:04 EDT Youngevity subsidiaries breaks ground in hemp grow project in Nicaragua - Youngevity International announced that its wholly-owned subsidiaries, CLR Roasters and Khrysos Industries, which are US Partners along with its Nicaraguan Partners have officially broken ground on the hemp grow and oil extraction joint venture project taking place on the 2,200 acre Chaguitillo Farms in Sebaco-Matagalpa, Nicaragua. The company announced the signing of the venture on April 21. The first phase of the development includes plans to run electricity that will power the 15,000 AMP electrical service that is necessary to power the project. The official electrical permits have been approved and the joint venture released a rendering of the project as an update to stakeholders and the community.

08:03 EDT Veritone receives two-year IDIQ contract for aiWARE platform from DOJ - Veritone announced that it has received a two-year indefinite delivery indefinite quantity, or IDIQ, contract for its aiWARE government platform from the U.S. Department of Justice, or DOJ. aiWARE government services may be ordered under the contract by the DOJ and the 94 United States Attorneys Offices throughout the country. The contract includes AI-enabled audio and video transcription and translation services powered by aiWARE. The DOJ identified aiWARE government as the sole source available to meet the DOJ's requirements for these AI-enabled services. The services can be accessed directly through the DOJ's eDiscovery platform to expedite evidence discovery, greatly reducing human labor and associated costs. Case teams can leverage aiWARE to support the search, discovery and analysis of large amounts of information, regardless of data type or language.

08:01 EDT Raytheon Technologies awarded $145M contract by U.S. Army - The U.S. Army Contracting Command has selected Raytheon Intelligence & Space, a business of Raytheon Technologies, to train Afghanistan Air Force pilots under a three-year contract valued up to $145M. Raytheon will conduct initial flight training for the U.S. Army's Program Executive Office for Simulation, Training and Instrumentation. The Afghanistan Air Force students will go through flight school in third-party nations in Europe and the Middle East. Raytheon will provide tailored training for the Afghanistan Air Force pilots, including classroom, fixed-wing and rotary aircraft instruction.

07:48 EDT Black Diamond expects to complete Phase 1 portion of BTDX-189 trial by 1H21 - Black Diamond continued to enroll and dose patients in the Phase 1 portion of a Phase 1/2 clinical trial of BTDX-189 and expects to complete the Phase 1 portion of the trial by the first half of 2021. BDTX-189 is Black Diamond's mutation spectrum-selective, oral, irreversible small molecule inhibitor product candidate, which targets cancer-causing driver mutations in human epidermal growth factor receptor 2 and epidermal growth factor receptor that have not yet been drugged.

07:46 EDT Black Diamond Therapeutics expects cash to fund operations into 2023

07:41 EDT Boeing CEO sees 'three full years' before traffic fully returns - Boeing CEO Dave Calhoun is speaking on NBC's "Today" show.

07:40 EDT Tonix says enrollment for Phase 3 RELIEF trial remains on schedule to date - In April 2020, Tonix announced that 50 percent enrollment had been achieved in the Phase 3 RELIEF trial, a potential pivotal study of TNX-102 SL 5.6 mg taken daily at bedtime for the management of fibromyalgia. An optional interim analysis of the first 50 percent of randomized participants that are evaluable for efficacy is expected to be conducted, with results expected in September 2020. The COVID-19 pandemic may also lead to a delay in recruitment of the second 50% of participants and topline results, but to date trial enrollment remains on schedule. The long-term safety exposure data of TNX-102 SL 5.6 mg collected in PTSD studies are expected to support the fibromyalgia New Drug Application.

07:35 EDT Cantel Medical takes actions to preserve cash flow - Given the COVID-related government lockdowns and social distancing initiatives, the company has seen a deferral of elective medical and dental procedures across markets in which Cantel operates. The company reacted early to these headwinds to ensure that it could protect its employees, deliver resilience across its supply chain and best position itself for the recovery period during which such deferred procedures will resume. Ultimately, the Company believes that the core value proposition of its 'complete circle of protection' offering of infection prevention solutions are even more critical and relevant as we serve customer needs in the post-COVID recovery. Operationally, the company has taken significant measures to ensure that its supply chain remains fully operational through the crisis, with all facilities open and manufacturing, while adhering to local regulations. The company has taken the following actions to preserve cash flow through this period: Deployed workforce furloughs across manufacturing sites experiencing declines in demand, along with temporary furloughs and decreases in pay for administrative personnel; Deferred all non-essential capital expenditures; Canceled all non-essential travel; Reduced inventory in areas where demand has decreased, including aggressive material management to limit purchasing; Suspended any dividend through at least October 31, 2021; Suspended and reduced executive salaries and Board of Directors compensation.

07:24 EDT Altimmune appoints Diane Jorkasky to board of directors - Altimmune announced the appointment of Diane Jorkasky, M.D. to its Board of Directors. With Dr. Jorkasky's appointment, the size of the board increased to eight members. Prior to her current roles, she was Chief Medical Officer and Head of Development of Complexa Inc., Chief Medical Officer of Endo Pharmaceuticals, and Chief Development and Medical Officer of Aileron Therapeutics.

07:19 EDT Galera expects cash, cash equivalents to fund requirements into 2H22 - As of March 31, 2020, Galera had cash, cash equivalents and short-term investments of $120.5 million. Galera expects that its existing cash, cash equivalents and short-term investments, together with the expected payments from Blackstone in the amount of $57.5 million upon the achievement of certain clinical enrollment milestones in the ROMAN trial and the anti-cancer program in combination with SBRT under the amended royalty agreement, will enable Galera to fund its operating expenses and capital expenditure requirements into the second half of 2022.

07:17 EDT Galera Therapeutics expects topline data from Phase 3 ROMAN trial in 2H21 - Updated guidance for topline data from the Phase 3 ROMAN clinical trial of avasopasem for the treatment of SOM in patients with locally advanced head and neck cancer receiving radiotherapy to the second half of 2021. COVID-19 has delayed the initiation of the Phase 2a multi-center trial in Europe in patients with head and neck cancer indefinitely. This trial was expected to enroll up to 70 patients and contribute to the safety database for avasopasem for SOM in head and neck cancer. As a result, in order to ensure we are positioned to maintain the size of the safety database, the ROMAN trial target enrollment has been increased to 450 patients. Continued enrollment in the Phase 2a clinical trial of avasopasem to evaluate its ability to reduce the incidence of radiation-induced esophagitis in patients with lung cancer.

07:13 EDT Cabaletta Bio plans to initiate Phase 1 trial of DSG3-CAART in 2020

07:11 EDT Green Thumb Industries to open Essence South Rainbow store - Green Thumb Industries announced it will open Essence South Rainbow, on May 13. This is the fourth Essence store in the Las Vegas area and GTI's 44th retail location in the nation. In addition to its retail business in Nevada, GTI owns three wholesale manufacturing sites in Nevada where it makes its branded products including Cannabiotix, Desert Grown Farms, Dogwalkers, incredibles and Rythm. GTI also has licenses to open seven more retail stores in the state. Essence South Rainbow offers pre-order for in-store pickup, curbside pickup and delivery.

07:10 EDT Helius Medical granted Breakhrough Device Designation for PoNS device - Helius Medical Technologies announced that it has received Breakthrough Designation for its PoNS device as a potential treatment for gait deficit due to symptoms of Multiple Sclerosis, to be used as an adjunct to a supervised therapeutic exercise program.

07:06 EDT Macerich is not providing updated outlook - On March 27 given the complex and rapidly evolving circumstances surrounding the COVID-19 pandemic, the Company withdrew its previously published 2020 Guidance, and is not providing an updated outlook at this time.

07:06 EDT Ocular Therapeutix doses firs patient in OTX-CSI Phase 1 clinical trial - Ocular Therapeutix announced that it has dosed the first patients in its Phase 1 clinical trial of OTX-CSI for the treatment of dry eye disease. The Phase 1 clinical trial is a U.S.-based, open label, single center trial that intends to enroll 5 subjects and follow them for approximately 4 months. The study will evaluate safety and tolerability of OTX-CSI and assess biological activity by measuring signs and symptoms of DED over this time period.

07:05 EDT BioXcel Therapeutics expects data from Phase 1b/2 study of BXCL701 in Q4 - After completing the Phase 1b safety lead-in, the Company has initiated the Phase 2 portion of the Phase 1b/2 trial of BXCL701 in combination with pembrolizumab for treatment emergent Neuroendocrine Prostate Cancer 0.3 mg of BXCL701 twice daily was found to be the recommended dose when used in combination with KEYTRUDA and this dose regime will be used for the efficacy assessment of the clinical program. The Company expects to report initial data from this trial in the fourth quarter of 2020. The open label Phase 2 basket trial evaluating the combination of BXCL701 and KEYTRUDA in patients with advanced solid cancers has been initiated. This study, which is being conducted at the MD Anderson Cancer Center, is following the dosing schedule used in the Phase 1b/2 study for tNEPC. The BXCL701 phase of the triple combination study of BXCL701, bempegaldesleukin and BAVENCIO in pancreatic cancer is expected to begin following Nektar and Pfizer's Phase 1b safety trial of a double combination of bempegaldesleukin and avelumab and the outcome of that trial.

07:03 EDT BioXcel Therapeutics says has not experienced 'significant' delays to trials - During the first quarter of 2020, the Company took steps in line with guidance from the U.S. Centers for Disease Control and Prevention and the State of Connecticut to protect the health and safety of its employees and the community. In particular, the Company implemented a work-from-home policy for all employees and has restricted on-site activities to certain chemical, manufacturing and control and clinical trial activities. To date, the Company has not experienced any significant delays to its ongoing or planned clinical trials; however, this could rapidly change.

06:47 EDT Babcock & Wilcox expects to complete financing process before May 15 - Babcock & Wilcox Enterprises, announced that the Company is nearing the completion of its financing process and expects to make an announcement regarding its debt refinancing on or before the May 15 deadline under its current amended Credit Agreement. The Company and its lenders are in the process of finalizing a definitive agreement for a longer-term credit extension.

06:46 EDT Waddell & Reed reports preliminary AUM $60.9B as of April 30 - Compared to $56B on March 31.

06:39 EDT NexGen Energy appoints Anthony George as Chief Project Officer - NexGen Energy announced the appointment of Tony George to the position of Chief Project Officer. Mr. George will commence in mid June and be responsible for execution of the company's 100% wholly owned Rook I Project through to production. Prior to joining NexGen, Tony served as Vice President Project Execution with Victoria Gold Corp.

06:36 EDT Ingersoll-Rand 'remains in a strong financial position with ample liquidity' - Ingersoll-Rand said, "The company remains in a strong financial position with ample liquidity of $1.6 billion, no debt maturities until 2027 and several opportunities to unlock cash as we look ahead. On a reported basis, Ingersoll Rand generated $68 million of cash flow from operating activities and invested $8 million in capital expenditures, resulting in free cash flow of $60 million, compared to cash flow from operating activities of $69 million and free cash flow of $55 million in the year-ago period. Operating cash flows in the first-quarter of 2020 include outflows of approximately $63 million related to the Transaction, including synergy delivery costs, stand-up costs and Transaction fees. First-quarter net debt to Supplemental Adjusted EBITDA leverage was 2.6x."

06:33 EDT Ingersoll-Rand expects to deliver 35% of $250M synergy target in 2020 - Through the Ingersoll Rand Execution Excellence process, the team has accelerated synergy actions. The company expects to deliver approximately 35% of the $250M synergy target in 2020, which is approximately three times higher than previously provided.

06:23 EDT Duke Energy backs FY20 CapEx plan of $11B-$12B - Says "2020 capital plan unchanged, but flexibility remains."

06:14 EDT Rubius Therapeutics presents preclinical data from aAPC program - Rubius Therapeutics presented preclinical data supporting its lead artificial antigen-presenting cell, or aAPC, program, RTX-321, for the potential treatment of HPV 16-positive tumors at the American Society of Gene and Cell Therapy 23rd Annual Meeting. The meeting is being held virtually from May 12 - 15. "Today, we presented preclinical in vitro data supporting the development of RTX-321 for the treatment of HPV 16-positive tumors by demonstrating that we can expand the different cell populations - effector and long-lived memory CD8+ cells - that are critical for delivering and maintaining long-term, anti-tumor responses in patients," said Laurence Turka, chief scientific officer of Rubius Therapeutics. "Additionally, we presented data showing that our aAPC platform can expand both naive and exhausted CD4+ T cells. CD4+ T cells help coordinate an immune response by stimulating other immune cells to fight cancer. By enhancing the expansion, persistence and functionality of both naive and exhausted CD4+ T cells, we may be able to harness the full complement of tumor-specific CD4+ T cells to achieve durable responses in patients with HPV 16-positive cancers. We plan to file an Investigational New Drug application for RTX-321 by the end of 2020."

06:07 EDT Farmmi subsidiary receives repeat order for Shiitake, black Mu Er mushrooms - Farmmi announced its subsidiary Zhejiang FLS continues to drive revenue growth with another repeat customer order for Shiitake and black Mu Er mushrooms. The latest order is from an existing customer, which distributes agriculture products in China.

06:04 EDT Dynatrace sees FY21 total unlevered free cash flow $180M-$190M

05:40 EDT Gamida Cell says Phase 3 clinical study of omidubicel met primary endpoint - Gamida Cell announced positive topline results from its Phase 3 clinical study evaluating the safety and efficacy of omidubicel, an investigational advanced cell therapy in development as a potential life-saving treatment option for patients in need of bone marrow transplant. The median time to neutrophil engraftment was 12 days for patients randomized to omidubicel compared to 22 days for the comparator group. Neutrophil engraftment is a measure of how quickly the stem cells a patient receives in a transplant are established and begin to make healthy new cells, and rapid neutrophil engraftment has been associated with fewer infections and shorter hospitalizations. Despite the curative potential of bone marrow transplant, it is estimated that more than 40 percent of eligible patients in the United States do not receive a transplant for various reasons, including the lack of a matched donor. Even for patients who do receive a transplant, treatment is not always effective and can lead to serious complications that can dramatically affect their quality of life. Omidubicel is intended to address the current limitations of bone marrow transplant by providing a therapeutic dose of stem cells while preserving the cells' functional therapeutic characteristics. The international, multi-center, randomized Phase 3 study was designed to evaluate the safety and efficacy of omidubicel in patients with high-risk hematologic malignancies undergoing a bone marrow transplant compared to a comparator group of patients who received a standard umbilical cord blood transplant. The primary endpoint was time to neutrophil engraftment. The intent-to-treat analysis included 125 patients aged 12-65 years with acute lymphoblastic leukemia, acute myelogenous leukemia, chronic myelogenous leukemia, myelodysplastic syndrome or lymphoma and was conducted at more than 50 clinical centers in the United States, Latin America, Europe and Asia. The demographics and baseline characteristics were well-balanced across the two study groups. The study achieved its primary endpoint. In the intent-to-treat analysis, the median time to neutrophil engraftment was significantly shorter for patients who received omidubicel compared to the comparator group. Omidubicel was generally well tolerated. Among patients who were transplanted per protocol, 96 percent of patients who received omidubicel achieved successful neutrophil engraftment, compared to 88 percent of patients in the comparator group.

05:26 EDT Sanofi says Phase 3 IKEMA clinical trial of Sarclisa met primary endpoint - The Phase 3 IKEMA clinical trial evaluating Sarclisa added to carfilzomib and dexamethasone met the primary endpoint at its first planned interim analysis, demonstrating significantly prolonged progression-free survival compared to standard of care carfilzomib and dexamethasone alone in patients with relapsed multiple myeloma. There were no new safety signals identified in this study. "When Sarclisa was added to standard-of-care treatment carfilzomib and dexamethasone in this phase 3 trial, results clearly demonstrated a significant reduction in risk of disease progression or death," said John Reed, M.D., Ph.D., Global Head of Research and Development at Sanofi. "This is the second positive phase 3 trial for Sarclisa, further supporting the potential our medicine has to improve outcomes for patients struggling with relapsed multiple myeloma." Results will be submitted to an upcoming medical meeting and are anticipated to form the basis of regulatory submissions planned for later this year.

05:09 EDT Salem Media announces temporary suspension of quarterly dividend due to COVID-19 - Salem Media Group announced that, due to uncertainty from the rapidly evolving impact of COVID-19 on the economy, Salem's board has made the decision, as part of a larger effort to conserve cash, to temporarily suspend the regular quarterly cash dividend on its common stock. The board will re-assess the dividend suspension throughout the year to determine, in light of facts and circumstances at that time, whether and when to reinstate the dividend. In addition to suspending the dividend, Salem implemented several cost reduction strategies designed to further preserve capital and liquidity, including, but not limited to, limiting capital expenditures, reducing discretionary spending such as travel and entertainment, eliminating open positions and new hires, reducing staffing when appropriate, requesting rent concessions from landlords, reducing employee compensation and requesting discounts from vendors. Taken together, Salem believes these are the right actions to successfully weather this challenging environment.